 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ETH-155008 / Shengke Pharmaceuticals
Enrollment change, Trial termination: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov) - Oct 11, 2023
P1a/1b, N=9, Terminated, Sponsor: Shengke Pharmaceuticals Pty Ltd
N=67 --> 9 | Recruiting --> Terminated; The reasons for early termination is due to slow recruitment
- ||| ETH-155008 / Shengke Pharmaceuticals
New P1 trial: A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients (clinicaltrials.gov) - Mar 7, 2023
P1, N=60, Recruiting, Sponsor: Shengke Pharmaceuticals (Jiangsu) Limited, China
- ||| ETH-155008 / Shengke Pharmaceuticals
Enrollment open: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov) - Feb 16, 2023
P1a/1b, N=67, Recruiting, Sponsor: Shengke Pharmaceuticals Pty Ltd
N=67 --> 9 | Recruiting --> Terminated; The reasons for early termination is due to slow recruitment Active, not recruiting --> Recruiting
- || ETH-155008 / Shengke Pharmaceuticals
Enrollment closed, Enrollment change: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov) - Feb 6, 2023
P1a/1b, N=9, Active, not recruiting, Sponsor: Shengke Pharmaceuticals Pty Ltd
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=67 --> 9
- ||| ETH-155008 / Shengke Pharmaceuticals
Enrollment open: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov) - Jul 5, 2021
P1a/1b, N=67, Recruiting, Sponsor: Shengke Pharmaceuticals Pty Ltd
Recruiting --> Active, not recruiting | N=67 --> 9 Not yet recruiting --> Recruiting
- | ETH-155008 / Shengke Pharmaceuticals
New P1 trial: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov) - Apr 12, 2021
P1a/1b, N=67, Not yet recruiting, Sponsor: Shengke Pharmaceuticals Pty Ltd